Altered platelet plug formation in hyperthyroidism and hypothyroidism
- PMID: 17488803
- DOI: 10.1210/jc.2006-2644
Altered platelet plug formation in hyperthyroidism and hypothyroidism
Abstract
Objective: Patients with thyroid diseases have abnormalities of blood coagulation including an alteration of von Willebrand factor (vWF) levels. Because vWF plays an important role in primary hemostasis, we hypothesized that heightened and decreased vWF levels in hyper- and hypothyroidism enhance and decrease platelet plug formation, respectively.
Methods: We followed a cohort of 120 patients with overt hyperthyroidism, patients with subclinical and overt hypothyroidism, and euthyroid controls. vWF and in vitro platelet plug formation as collagen-epinephrine-induced closure time (CEPI-CT) were measured at baseline and during therapy with thiamazole or T(4).
Results: Baseline vWF levels were higher in patients with hyperthyroidism and lower in patients with overt hypothyroidism than in controls (P < 0.01). High vWF antigen levels were associated with increased baseline platelet plug formation in patients with hyperthyroidism as compared with controls [114 sec (95% confidence interval, 105-122 sec) vs. 130 sec (120-140 sec), P = 0.01]. After 8 wk of therapy with thiamazole, serum concentrations of T(4) and vWF levels decreased to normal values (P < 0.01 vs. baseline), and CEPI-CT was prolonged as compared with baseline (P < 0.01). During therapy with T(4), vWF levels increased (P < 0.05 vs. baseline) and CEPI-CT was shortened as compared with baseline (P < 0.01).
Conclusion: Hyperthyroidism-induced vWF elevation is associated with enhanced platelet function and therefore shortened CEPI-CT values. These changes may contribute to the higher risk for cardiovascular disease in patients with hyperthyroidism. Platelet plug formation decreases during therapy with thiamazole. Furthermore, CEPI-CT appears to be sensitive to detect acquired von Willebrand disease associated with overt hypothyroidism.
Similar articles
-
Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism.Eur J Endocrinol. 2005 Mar;152(3):355-61. doi: 10.1530/eje.1.01857. Eur J Endocrinol. 2005. PMID: 15757851 Clinical Trial.
-
Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study.Haemophilia. 2014 May;20(3):326-32. doi: 10.1111/hae.12275. Epub 2013 Oct 14. Haemophilia. 2014. PMID: 24118466
-
Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals.Br J Haematol. 2005 Sep;130(5):759-67. doi: 10.1111/j.1365-2141.2005.05680.x. Br J Haematol. 2005. PMID: 16115134
-
[Thyroid dysfunction in pregnant women: clinical dilemmas].Ned Tijdschr Geneeskd. 2012;156(49):A5163. Ned Tijdschr Geneeskd. 2012. PMID: 23218031 Review. Dutch.
-
Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays.Blood Coagul Fibrinolysis. 2011 Oct;22(7):553-64. doi: 10.1097/MBC.0b013e32834a7e01. Blood Coagul Fibrinolysis. 2011. PMID: 21885953 Review.
Cited by
-
Unexpected Grave's-induced acute myocardial infarction in a young female, a literature review based on a case report.Int J Emerg Med. 2024 Sep 4;17(1):111. doi: 10.1186/s12245-024-00695-1. Int J Emerg Med. 2024. PMID: 39232679 Free PMC article.
-
Thyroid hormones and platelet activation in COVID-19 patients.J Endocrinol Invest. 2023 Feb;46(2):261-269. doi: 10.1007/s40618-022-01896-2. Epub 2022 Sep 5. J Endocrinol Invest. 2023. PMID: 36064879 Free PMC article.
-
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.Endocrine. 2009 Feb;35(1):75-80. doi: 10.1007/s12020-008-9116-4. Epub 2008 Oct 29. Endocrine. 2009. PMID: 18958631
-
Sinus sigmoideus thrombosis secondary to graves' disease: a case description.Case Rep Neurol. 2011 Sep;3(3):203-9. doi: 10.1159/000331448. Epub 2011 Sep 7. Case Rep Neurol. 2011. PMID: 22114580 Free PMC article.
-
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.Endocrine. 2009 Dec;36(3):473-8. doi: 10.1007/s12020-009-9271-2. Epub 2009 Oct 27. Endocrine. 2009. PMID: 19859836
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous